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A B S T R A C T
Purpose
We conducted a randomized trial comparing adjuvant treatment with edrecolomab versus
observation in patients with resected, low-risk, stage II colon cancer. This study also prospectively
studied patient- and tumor-specific markers of treatment outcome.
Patients and Methods
After surgical resection, patients with stage II colon cancer were randomly assigned to either five
infusions of edrecolomab at 28-day intervals or observation without adjuvant therapy.
Results
Final accrual included 1,738 patients; 865 patients received edrecolomab, and 873 patients were
observed without adjuvant treatment. Median follow-up time was 7.9 years. There were no
significant outcome differences between study arms (overall survival [OS], P  .71; disease-free
survival, P  .64). The combined 5-year all-cause OS was 0.86 (95% CI, 0.84 to 0.88), and the
combined 5-year disease-specific OS was 0.93 (95% CI, 0.91 to 0.94). The relationships between
demographic and histopathologic factors and survival differed for all-cause and disease-specific
survival outcomes, but no combined prognostic factor model was found to adequately classify
patients at higher risk of recurrence or death as a result of colon cancer.
Conclusion
Edrecolomab did not prolong survival. Consequently, this large study with a long duration of
follow-up provided unique data concerning the natural history of resected stage II colon cancer.
Prognostic factors identified in previous retrospective and pooled analyses were associated with
survival outcomes in this stage II patient cohort. Results from ongoing molecular marker studies
may enhance our ability to determine the risk profile of these patients.
J Clin Oncol 29:3146-3152. © 2011 by American Society of Clinical Oncology
INTRODUCTION
For patients with colon cancer, prognosis after sur-
gical resection is directly related to the pathologic
stage, with relative 5-year survival rates of greater
than 90% if the tumor is restricted to the submucosa
(T1-2, N0) and less than 10% if distant metastases
have developed.1 During the 1990s, adjuvant chem-
otherapy with fluorouracil (FU) and leucovorin be-
came the standard of care for patients with stage III
(node-positive) colon cancer, although the benefit
for patients with stage II (node-negative) disease was
unclear.2-5 Early intergroup studies documenting
the efficacy for patients with stage III disease receiv-
ing FU-based combination chemotherapy did not
always show the same degree of efficacy among pa-
tients with stage II disease.6-10 In addition, no signif-
icant differences among patients with stage II disease
have been reported from recent trials of oxaliplatin
with FU, although trends have been noted.11-13 In
1990, a National Institutes of Health consensus
panel recommended against adjuvant therapy for
patients with stage II colon cancer.14 Again in 2004,
an American Society of Clinical Oncology panel
concluded that the routine use of adjuvant chemo-
therapy for patients with stage II colon cancer was
not directly supported by the results of randomized
controlled trials. Patient-physician discussion re-
garding the risks and potential benefits of treat-
ment was recommended, with the suggestion that
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adjuvant therapy be considered for high-risk patients, such as those
presenting with T4 lesions, perforation, peritumoral lymphovascular
invasion, poorly differentiated histology, and inadequate lymph node
assessment.15 Similar recommendations were made in the National
Comprehensive Cancer Network Clinical Practice Guidelines in On-
cology in 2010.16 However, these recommendations have never been
validated in the setting of a prospective clinical trial. Thus, the benefit
of adjuvant chemotherapy in stage II colon cancer remains uncertain.17,18
Edrecolomab is a murine immunoglobulin G2a monoclonal
antibody directed against a transmembrane glycoprotein preferen-
tially expressed on many adenocarcinomas.19 This agent mediates
tumor suppression through antibody-dependent, cell-mediated,
and complement-dependent cellular cytotoxicity, and these char-
acteristics allow it to preferentially target and lyse cancer cells.20-25
On the basis of results from an early clinical trial,26 the Cancer and
Leukemia Group B (CALGB) initiated a study of edrecolomab
versus a no-treatment control for patients with stage II colon
cancer whose tumors did not have the high-risk clinical character-
istics of obstruction or perforation. Collection of tissue samples to
prospectively study prognostic and predictive biomarkers was also
an important component of the trial. This article provides the final
results of the clinical aspects of the study, with a focus on the
characteristics of this prospectively studied, stage II patient cohort
illustrating the natural history of stage II colon cancer.
PATIENTS AND METHODS
Trial Conduct
CALGB developed and coordinated this trial. Participants included the
Eastern Cooperative Oncology Group, Southwest Oncology Group, North
Central Cancer Treatment Group, National Cancer Institute Expanded Par-
ticipation Project, Cancer Research Clinical Trials Unit, National Cancer In-
stitute of Canada Clinical Trials Group, and European Organisation for
Research and Treatment of Cancer. Institutional review board approval and
patient informed consent were required at each participating center. Patient
registration and data collection were managed by the CALGB Statistical Cen-
ter. Quarterly electronic reporting to the Clinical Therapy Evaluation Program
was made via the Clinical Data Update System. Safety and efficacy data were
reviewed by the CALGB Data and Safety Monitoring Board according to
CALGB policies and procedures. Data quality was ensured by careful review of
data by CALGB Statistical Center staff and by the study chairperson. Statistical
analyses were performed by CALGB statisticians.
Eligibility Criteria
Eligible patients had undergone complete en bloc resection of an adeno-
carcinoma of the colon with no lymph node metastases (stage II, defined as
pT3N0 or pT4aN0 lesions excluding pT4bN027,28; modified Astler-Coller
stage B2) and no perforation or obstruction. Surgery must have been by open
procedure with a minimum of three nodes sampled. Eligible patients were 18
years of age or older, had no prior cancer within 5 years (except nonmelanoma
skin cancer or cervical carcinoma in situ), and had no previous radiation or
chemotherapy for this malignancy. Eligible patients also had CALGB perfor-
mance status of 0 (fully active) or 1 (capable of light work), no concurrent
treatment with systemic corticosteroids, no prior exposure to murine antibod-
ies, and no uncontrolled or severe cardiovascular disease. Although not a strict
eligibility criterion, the protocol recommended initiation of treatment no
earlier than 7 days and no later than 42 days after resection.
Statistical Methods
Patients were randomly assigned with equal probability to treatment
with edrecolomab or observation, stratified by tumor degree of differentiation,
lymphovascular invasion, and preoperative serum carcinoembryonic antigen
(CEA) level. The primary end point was overall survival (OS); secondary end
points included disease-free survival (DFS) and the relationships between
tumor- and patient-specific prognostic factors and OS and DFS. The trial was
designed to detect an OS hazard ratio of 1.5 for observation versus treatment
with edrecolomab based on the log-rank test (one-sided   .05). Analyses
were performed according to intent to treat.
Survival curves were estimated using the Kaplan-Meier method. The
primary hypothesis was tested using the Cox proportional hazards model
adjusting for the stratification factors.29,30 The proportional hazards model
was also used for multivariable modeling using the methods described by
Harrell et al.31,32 The log-rank test was used for univariable comparisons of
time-to-event end points.33
The following prognostic factors were studied for association with OS
and DFS: sex, race (white v nonwhite), age (actual value and  v  70
years), tumor differentiation (well or moderate v poor or undifferenti-
ated), lymphovascular invasion (no v yes), performance status (0 v 1)
preoperative CEA ( v  5 ng), tumor location (proximal v distal),
number of nodes examined (actual value and  v  12 nodes), T stage
(T1-3 v T4), perineural invasion (no v yes), and peritumoral host lymphoid
reaction (no v yes).
An OS event was defined as a death from any cause, and a DFS event was
defined as a documented recurrence of primary disease or death from any
cause. In additional analyses, disease-specific OS and DFS events were defined
as documented death as a result of disease and documented recurrence of
primary disease or death as a result of disease, respectively. New primary
cancers were considered non–disease-related events. A non–cancer-related
OS event was defined as a death documented as attributable to causes other
than disease. In the analyses of disease-specific end points, other causes of
death were censored. Data completeness for survival was assessed using
Wu’s criterion.34
The statistical methods proposed by Gray for the analysis of the
cumulative incidence of competing risks were used to investigate the
impact of prognostic factors on disease-related and other cause–related
mortality.35,36 Smoothing splines were used to model the relationships
between the log hazard ratios for time-to-event end points and continuous
prognostic factors.37 All analyses were conducted using SAS version 9.1.3
(SAS Institute, Cary, NC) or R38 on the study database frozen on December
4, 2009.
Treatment, Dose Modifications, and Adverse Events
Therapy consisted of an initial 2-hour infusion of 500 mg of edreco-
lomab (cycle 1) followed by 100 mg every 28 days for four additional cycles (a
total of approximately 20 weeks of therapy). Any grade 3 or 4 adverse event
occurring during or immediately after infusion or between infusions resulted
in treatment discontinuation. Data on adverse events were obtained using the
CALGB Expanded Common Toxicity Criteria.
Follow-Up
Physical examinations occurred within 2 days before day 1 of each
28-day cycle during treatment with edrecolomab and within 7 days of random
assignment and at 3 months and 6 months after random assignment for
patients on observation. Patients on both study arms were then observed by
physical examinations every 6 months and annual imaging to detect recur-
rence or second malignancy. For patients on the edrecolomab treatment arm,
assessments of adverse events were also conducted. Full data reporting was
required at the time of any disease occurrence or recurrence and at death for
patients on both arms.
RESULTS
This study was activated on May 31, 1997. On the basis of the initial
and disappointing results of studies conducted in stage III colon can-
cer,39,40 enthusiasm for further investigation of the edrecolomab anti-
body was severely diminished, and CALGB 9581 was closed to accrual
on May 31, 2002 as a result of permanent discontinuation of the drug
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supply. The final patient accrual was 1,738 of the planned 2,100 pa-
tients (edrecolomab, 865 patients; observation, 873 patients). Figure 1
depicts patient flow on study. Because of a computer error in the
random assignment algorithm that occurred between January 5, 2000,
and February 8, 2000, 25 patients received a treatment assignment but
were not randomly assigned. These patients were excluded from the
analysis. Thus, the final primary analysis included 1,713 patients, 857
randomly assigned to edrecolomab and 856 randomly assigned to
observation. Of the 857 patients assigned to treatment with edreco-
lomab, 834 patients started treatment and 722 of these patients
(86.6%) reported completing treatment.
For 834 patients with data available who were randomly assigned
and started protocol therapy, the median time between resection and
start of treatment was 40 days (range, 0 to 94 days). Patient and tumor
characteristics were well balanced between treatment arms (Appendix
Table A1, online only).
A maximum of grade 3 toxicity was reported for 242 (29.4%)
of 823 participants reporting adverse events on edrecolomab, and
48 of patients (5.8%) experienced a maximum grade 4 toxicity. No
individual adverse event was reported in more than 5% of patients.
The most prevalent adverse event was diarrhea, with 4.1% of
patients experiencing a maximum of grade 3 or 4. One patient died
as a result of respiratory arrest secondary to hemoptysis within 30
days of completing treatment with edrecolomab; the death was not
attributed to treatment.
Treatment Efficacy
As of December 2009, data completeness for OS is 80% by Wu’s
criterion.41 Median follow-up time among surviving patients is 7.9
years on both treatment arms. Median times to OS and DFS have not
been reached. Total all-cause deaths were 180 on edrecolomab and
186 on observation. Of these 366 patients who died, 203 (55.4%) died
without evidence of colon cancer. Overall, 162 deaths (44.2%), 79 on
edrecolomab and 83 on observation, were reported as being a result of
causes other than the primary colon cancer. Disease-related death was
reported for 146 patients (39.8%). Cause of death was not available for
58 patients (15.8%).
Four hundred fifty-seven treatment failures, defined as disease
recurrence or death from any cause, have been reported (233 on the
edrecolomab arm and 224 on the observation arm). Ninety-one pa-
tients survived with disease recurrence, and 1,256 patients were alive
and disease free at the time of analysis. There were no significant
survival differences in OS or DFS between treatment arms (Table 1;
Fig 2).
Prognostic Factors
Results of univariable analyses based on the primary defini-
tions of OS and DFS are listed in Table 2. Survival estimates at 5
years are listed in Appendix Table A2 (online only). Worse out-
comes were associated with male sex, older age, the presence of
lymphovascular invasion, performance status less than fully active,
T4 tumor stage, preoperative CEA greater than 5 ng (marginally for
OS), less than 12 lymph nodes examined, perineural invasion
(marginally for DFS), and lack of peritumoral host lymphoid reac-
tion (marginally for DFS). Poor or undifferentiated tumor was
significantly associated with worse OS. No other significant differ-
ences were observed.
We analyzed outcomes according to disease-specific death,
with non– cancer-related causes of death censored (Table 3 and
Appendix Fig A1, online only; disease-specific survival estimates at
5 years are listed in Appendix Table A3, online only). Greater depth
of tumor invasion, less than 12 nodes examined (categorized at the
median; marginal for OS), and perineural invasion remained sig-
nificant predictors of worse disease-specific OS and DFS. Male sex
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Fig 1. Patient flow diagram for Cancer
and Leukemia Group B 9581 study. MoAb
17-1A, edrecolomab.
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invasion, and poor or undifferentiated tumor were significant pre-
dictors of worse OS. Associations of race (OS and DFS), tumor
location (DFS), and number of nodes examined (actual value and
categorized; DFS) were also significant predictors of disease-
specific outcomes. The log hazard for disease-specific DFS de-
creased linearly with increasing number of nodes examined, and
there seems to be a threshold for increasing log hazard among
patients older than age 70 years (Fig 3).
An analysis using a competing risk model for disease-related
mortality versus other cause–related mortality (Appendix Table A4
and Fig A2, online only) revealed a significant sex difference, with a
higher cumulative probability of death from other causes in men
(P  .03). The cumulative probability for disease-related mortality
between whites and nonwhites was also significant, with whites having
a lower incidence of events (P  .01). In addition, under the cumula-
tive incidence model, patients age 70 years or older at study entry did
not experience significantly greater disease-related mortality than
younger patients (P  .15); however, the difference in other cause–
related mortality was highly significant (P  .001). Significant disease-
related OS differences were also found for cumulative incidence by
differentiation (P  .005), lymphovascular invasion (P  .02), depth
of tumor invasion (P  .001), number of nodes examined (P  .001),
and perineural invasion (P .001). Significant other cause–related OS
differences were also found for cumulative incidence by lymphovas-
cular invasion (P  .02), performance status (P  .001), and number
of nodes examined (P  .001).
Multivariable Analysis
Regression modeling was used to determine the simultaneous
association between study variables and survival outcomes. For
disease-specific OS, nonwhite race (P  .006), older age (P  .02),
poor tumor differentiation (P  .001), greater depth of tumor inva-
sion (P  .005), distal location (P  .03), and the presence of perineu-
ral invasion (P  .001) were simultaneously associated with worse
outcome. For non–cancer-related OS, male sex (P  .001), older age
(P .001), poor performance status (P .001), and less than 12 nodes
examined (P  .008) simultaneously predicted for worse outcome.
For disease-specific DFS, race (P  .05), depth of tumor invasion
(P  .04), the presence of perineural invasion (P  .04), tumor
location (P  .02), and fewer number of nodes examined (P  .03)
were significantly associated with worse outcome.
Multivariate analyses of the cumulative incidence of disease-
related and non–cancer-related mortality produced similar results,
except that age was not significant in the model of disease-related OS.
No combined prognostic factor model was found to be sufficiently
predictive for disease-specific OS and DFS.
Table 1. Five- and 7-Year All-Cause and Disease-Specific OS and DFS, Overall and by Treatment Arm
Outcome
5-Year Results 7-Year Results
Edrecolomab Observation Combined Edrecolomab Observation Combined
All-cause OS 0.87 0.85 0.86 0.80 0.79 0.80
95% CI 0.85 to 0.90 0.82 to 0.88 0.84 to 0.88 0.77 to 0.83 0.76 to 0.82 0.77 to 0.82
Disease-specific OS 0.92 0.93 0.93 0.91 0.90 0.90
95% CI 0.90 to 0.94 0.91 to 0.94 0.91 to 0.94 0.88 to 0.92 0.87 to 0.92 0.88 to 0.91
All-cause DFS 0.80 0.80 0.80 0.73 0.75 0.74
95% CI 0.77 to 0.83 0.77 to 0.82 0.78 to 0.82 0.70 to 0.76 0.72 to 0.78 0.72 to 0.76
Disease-specific DFS 0.83 0.85 0.85 0.82 0.84 0.83
95% CI 0.80 to 0.86 0.83 to 0.88 0.83 to 0.87 0.79 to 0.85 0.81 to 0.87 0.81 to 0.85
Abbreviations: OS, overall survival; DFS, disease-free survival.
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Fig 2. Kaplan-Meier estimates of (A) overall survival (all-cause death) by treatment (stratified proportional hazards, P  .71) and (B) disease-free survival (documented
recurrence of primary colon cancer or death from any cause) by treatment (stratified proportional hazards, P  .64).
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DISCUSSION
On the basis of a promising published report of a randomized trial in
189 patients with stage III disease,26 CALGB investigators sought to
determine whether the use of edrecolomab, a relatively nontoxic ad-
juvant therapy, would demonstrate a benefit in a cohort of patients
with stage II colon cancer that excluded patients with such high-risk
factors as tumor perforation and obstruction. Unfortunately, as the
results of C9581 show, this much larger trial of 1,713 patients with stage II
disease provides further evidence that the administration of edrecolomab
does not improve outcome for such patients. In retrospect, this negative
outcome is not surprising. Neither of two randomized trials, initiated in
the mid-1990s and conducted in North and South America39 and Eu-
rope,40 showed a significant benefit for adding edrecolomab to FU/
leucovorin-based therapy for patients with stage III colon cancer.
CALGB 9581 generated an observational data set of uniformly
staged and treated patients describing the prognosis of untreated stage
II disease.27,28,42 The 5-year all-cause OS in this cohort was 0.86, with a
5-year disease-specific OS of 0.93. With such a remarkable OS and small
probability of disease-related death, it would be extremely difficult to
Table 2. Statistical Significance for OS and DFS by Treatment and Prognostic Factors for Death From All Causes
Factor No. of Patients P  for OS (n  366 events) P  for DFS (n  457 events)
Treatment† 1,713 .71 .64
Sex 1,713  .001  .001
Race 1,707 .24 .12
Age‡ 1,713  .001  .001
Age ( v  70 years) 1,713  .001  .001
Differentiation (stratification factor) 1,713 .48 .71
Differentiation (well/moderate v poor/undifferentiated) 1,694 .04 .25
Vascular/lymphatic invasion (stratification factor) 1,713 .0049 .005
Performance status 1,697  .001  .001
Depth of tumor invasion (T1-3 v T4) 1,702 .006 .013
Preoperative CEA (stratification factor) 830 .06 .019
Tumor location 1,701 .77 .13
No. of nodes examined‡ 1,702 .012  .001
No. of nodes examined ( v  12) 1,702  .001  .001
Perineural invasion 1,692 .025 .06
Peritumoral host lymphoid reaction 1,675 .048 .06
Abbreviations: OS, overall survival; DFS, disease-free survival; CEA, carcinoembryonic antigen.
P values are associated with the log-rank test unless otherwise noted.
†Stratified proportional hazards model.
‡Proportional hazards model.




P  for Disease-Specific OS
(n  146 events)
P  for Disease-Specific DFS
(n  265 events)
P  for Non–Cancer-Related OS
(n  162 events)
Treatment† 1,655 .91 .44 .72
Sex 1,655 .05 .09 .026
Race 1,649 .004 .002 .12
Age‡ 1,655 .031 .23  .001
Age ( v  70 years) 1,655 .06 .22  .001
Differentiation (stratification factor) 1,655 .46 .71 .57
Differentiation (well/moderate v poor/undifferentiated) 1,636 .004 .24 .55
Vascular/lymphatic invasion (stratification factor) 1,655 .013 .09 .013
Performance status 1,639 .35 .24  .001
Depth of tumor invasion (T1-3 v T4) 1,642  .001 .02 .21
Preoperative CEA (stratification factor) 807 .46 .04 .08
Tumor location 1,643 .08 .002 .14
No. of nodes examined‡ 1,644 .17 .009 .007
No. of nodes examined ( v  12) 1,644 .06 .003  .001
Perineural invasion 1,634  .001 .02 .80
Peritumoral host lymphoid reaction 1,617 .26 .26 .24
NOTE. Analysis of the DFS endpoint includes 12 additional patients who died after recurrence of disease with unknown cause of death.
Abbreviations: OS, overall survival; DFS, disease-free survival; CEA, carcinoembryonic antigen.
P values are associated with the log-rank test unless otherwise noted.
†Stratified proportional hazards model.
‡Proportional hazards model.
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demonstrate a benefit for any adjuvant therapy in such a population of
patientswithstageIIcoloncancerwithoutaccruingthousandsofpatients.
Our data show that it is important to distinguish between
disease-related and other causes of death in this low-risk, older
patient population with stage II disease. We found large differences
in outcome by sex and age for all-cause mortality that were primar-
ily caused by association of these factors with death as a result of
other causes. It is not surprising that study patients older than age
70 years would have more comorbid conditions and a correspond-
ing greater probability of non– cancer-related death than patients
less than 70 years of age entered onto this trial. Particularly inter-
esting findings were the differences in treatment outcome according to
race, with race being significantly associated with disease-specific
OS and DFS and disease-related cumulative incidence in multi-
variable analyses. The nonwhite category of race comprised a mix-
ture of racial and ethnic minorities that were putatively treated per
protocol. No difference in outcome across these subgroups was
observed, although sample sizes were small. Differences by race in
this study may be partially explained by the apparent poorer sur-
vival among nonwhite patients who did not meet the study eligi-
bility criteria (v both whites and nonwhites who did meet study
eligibility), although, again, sample sizes were small (six deaths in
19 patients). The results from this study suggest that the racial/
ethnic composition of study populations with stage II colon cancer
should be considered in the design of future trials. We also found a
strongly negative prognosis when fewer nodes were examined,
reinforcing previously published results.43,44 Interestingly, there
seems to be a continuous linear effect with no threshold.
We used two approaches to analyze these data. First, we de-
fined recurrence or disease-specific death as an event and censored
deaths as a result of other causes. A drawback of this approach is
that the assumption of independence between the event and the
censoring distribution may not hold because of an underlying relation-
ship between DFS and OS. The second method, using analysis of cumu-
lative incidence, allows the two outcome types (disease related and other
cause related) to be modeled simultaneously. A limitation of this method
is that itunrealisticallyassumesthat theriskset includespatientswhohave
experiencedfailurefromothercausesbeforetime t.Cumulativeincidence
is also sometimes misinterpreted as an estimate of the survival distribu-
tion. In both methods, data on cause of death were missing for 15% of
patients. Despite these drawbacks, we found that the results of the two
analysis methods were generally consistent, and results for the cumulative
incidence of other cause–related mortality were also reasonable in most
cases. Two exceptions are the significant relationships of lymphovascular
invasion and number of nodes examined with non–cancer-related OS
andthecumulative incidenceofothercause–relatedOS.Lymphovascular
invasion is no longer significant in the multivariable model, reflecting the
dominantinfluenceofsex,age,andperformancestatus.Numberofnodes
examined remained significant; the reason is not apparent but may be a
result of confounding with unknown factors.
Given the results obtained in this relatively homogenous pa-
tient cohort, regression modeling was also used to potentially
develop a predictive model for disease-specific OS and DFS. Un-
fortunately, no model was sufficiently predictive to propose for
validation, illustrating the difficulty of identifying patients at
higher risk using known prognostic factors. Analysis of the impact
of additional biomarkers and histologic factors at study entry on
outcome is under way and should provide new information re-
garding the risk profile of these patients.
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Fig 3. Smoothing splines of (A) the log hazard for disease-specific disease-free survival by number of nodes examined truncated at 32 nodes, representing 95% of
the data, and (B) the log hazard for disease-specific overall survival by age at trial entry with 95% confidence bands.
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